Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments
- 11 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 80 (5), 467-475
- https://doi.org/10.1007/s40265-020-01278-z
Abstract
Increased hepatic glucose output, the primary liver dysregulation associated with Type 2 diabetes mellitus (T2DM), is not directly or effectively targeted by the currently available classes of glucose-lowering medications except metformin. This unmet need might be addressed through activation of a specific enzyme-member of the hexokinase family, namely glucokinase (GK). GK serves as a “glucose-sensor” or “glucose receptor” in pancreatic cells, eliciting glucose-stimulated insulin secretion, and as glucose “gate-keeper” in hepatocytes, promoting hepatic glucose uptake and glycogen synthesis and storage. GK activation by small molecules present an alternative approach to restore/improve glycaemic control in patients with T2DM. GK activators (GKAs) may increase insulin secretion from the pancreas and promote glycogen synthesis in the liver, and hence reduce hepatic glucose output. Despite several setbacks in their development, interest in the GKA class has been renewed, particularly since the introduction of a novel, dual-acting full GKA, dorzagliatin, and a novel hepatoselective molecule, TTP399. In this article we provide an overview of the role, efficacy, safety and future developments of GKAs in the management of T2DM.Keywords
This publication has 50 references indexed in Scilit:
- Achievement of guideline targets for blood pressure, lipid, and glycaemic control in type 2 diabetes: A meta-analysisDiabetes Research and Clinical Practice, 2018
- All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: A population-based, open cohort studyDiabetes & Metabolism, 2017
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network DatabaseJournal of Clinical Endocrinology & Metabolism, 2017
- Targeting hepatic glucose metabolism in the treatment of type 2 diabetesNature Reviews Drug Discovery, 2016
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitusNature Reviews Endocrinology, 2016
- The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification SchemaDiabetes Care, 2016
- Novel therapeutics for type 2 diabetes: insulin resistanceDiabetes, Obesity and Metabolism, 2014
- Management of type 2 diabetes: new and future developments in treatmentThe Lancet, 2011
- Exploring thein VivoMechanisms of Action of Glucokinase Activators in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2010
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009